Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tenecteplase: A review
Autore:
Davydov, L; Cheng, JWM;
Indirizzi:
CUNY, Mt Sinai Med Ctr, New York, NY 10029 USA CUNY New York NY USA 10029CUNY, Mt Sinai Med Ctr, New York, NY 10029 USA Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NYUSA Long Isl Univ Brooklyn NY USA rtz Coll Pharm & Hlth Sci, Brooklyn, NYUSA
Titolo Testata:
CLINICAL THERAPEUTICS
fascicolo: 7, volume: 23, anno: 2001,
pagine: 982 - 997
SICI:
0149-2918(200107)23:7<982:TAR>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYOCARDIAL-INFARCTION; TISSUE-PLASMINOGEN-ACTIVATOR; FIBRIN-SPECIFICITY; THROMBOLYTIC THERAPY; KHRR-296-299 AAAA; DRUG DESIGN; PHASE-II; TRIAL; TIMI; VARIANT;
Keywords:
tenecteplase; thrombolytic; acute myocardial infarction; clinical pharmacology;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
44
Recensione:
Indirizzi per estratti:
Indirizzo: Cheng, JWM CUNY, Mt Sinai Med Ctr, Box 1211,1 Gustave L Levy Pl, New York,NY 10029 USA CUNY Box 1211,1 Gustave L Levy Pl New York NY USA 10029 029 USA
Citazione:
L. Davydov e J.W.M. Cheng, "Tenecteplase: A review", CLIN THER, 23(7), 2001, pp. 982-997

Abstract

Background: Certain shortcomings of the available thrombolytic agents haveprompted the search for a more fibrin specific fibrinolytic agent with a longer half-life. Such properties would allow bolus administration, possiblyleading to faster reperfusion of occluded arteries. Objective: This article focuses on the new thrombolytic agent tenecteplase, reviewing its mechanism of action, pharmacokinetic characteristics, clinical efficacy, tolerability, and potential for drug interactions in the management of acute myocardial infarction. Methods: English-language articles for inclusion in this review were identified through searches of MEDLINE (R), EMBASE (R), and International Pharmaceutical Abstracts from 1966 to April 2001. The search terms used included tenecteplase, myocardial infarction, TNK, and TNK-tPA. Abstracts from recent conferences and symposia were also consulted. Results: Tenecteplase is a variant of the native tissue-type plasminogen activator (tPA) molecule that has 14-fold greater fibrin specificity than alteplase, a longer half-life, slower plasma clearance, and 80-fold greater resistance to inhibition by plasmainogen activator inhibitor type 1. Its half-life of similar to 18 minutes allows single-bolus administration. In comparative clinical trials, tenecteplase was found to have equivalent efficacyto recombinant tPA (alteplase). The rate of intracranial. hemorrhage with tenecteplase was similar to that with alteplase, and tenecteplase was associated with fewer noncerebral complications and less need for blood transfusions. Conclusions: Tenecteplase appears to be as effective and well tolerated asalteplase in the management of acute myocardial infarction and offers the convenience of single-bolus administration.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/09/20 alle ore 07:38:46